• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Var

tetano

Editor, Senior Moderator
J Infect Dis


. 2022 Sep 20;jiac385.
doi: 10.1093/infdis/jiac385. Online ahead of print.
Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants


Camino Trobajo-Sanmartín[SUP] 1 2 3 [/SUP], Ana Miqueleiz[SUP] 3 4 [/SUP], Marcela Guevara[SUP] 1 2 3 [/SUP], Miguel Fernández-Huerta[SUP] 3 4 [/SUP], Cristina Burgui[SUP] 1 2 3 [/SUP], Itziar Casado[SUP] 1 2 3 [/SUP], Fernando Baigorria[SUP] 1 [/SUP], Ana Navascués[SUP] 3 4 [/SUP], Carmen Ezpeleta[SUP] 3 4 [/SUP], Jesús Castilla[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Background: We compare the risk of coronavirus disease 2019 (COVID-19) outcomes among co-circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants between January 2021 and May 2022 in Navarra, Spain.
Methods: We compared the frequency of hospitalization and severe disease (intensive care unit admission or death) due to COVID-19 among the co-circulating variants. Variants analyzed were non-variants of concern (non-VOCs), Alpha, Delta, Omicron BA.1, and Omicron BA.2. Logistic regression models were used to estimate adjusted odds ratio (aOR).
Results: The Alpha variant had a higher risk of hospitalization (aOR, 1.86 [95% confidence interval {CI}, 1.28-2.71]) and severe disease (aOR, 2.40 [95% CI, 1.31-4.40]) than non-VOCs. The Delta variant did not show a significantly different risk of hospitalization (aOR, 0.73 [95% CI, .40-1.30]) and severe disease (aOR, 3.04 [95% CI, .57-16.22]) compared to the Alpha variant. The Omicron BA.1 significantly reduced both risks relative to the Delta variant (aORs, 0.28 [95% CI, .16-.47] and 0.23 [95% CI, .12-.46], respectively). The Omicron BA.2 reduced the risk of hospitalization compared to BA.1 (aOR, 0.52 [95% CI, .29-.95]).
Conclusions: The Alpha and Delta variants showed an increased risk of hospitalization and severe disease, which decreased considerably with the Omicron BA.1 and BA.2. Surveillance of variants can lead to important differences in severity.

Keywords: Alpha variant; COVID-19; Delta variant; Omicron variant; SARS-CoV-2 variants; hospitalization; severe disease; variant of concern.
 
Back
Top Bottom